Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pactimibe, nevanimibe, benfluorex | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5173
Sealed predictions
- SOAT1 in dopamine neurons, braak+0.17 (p 0.663) → -0.20 (p 0.615)receipt 5180
Swarm cases
receipt 5180: SOAT1 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.874, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.894, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.854, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.06, sign flips 6; without severely affected donors -0.04 (p 0.874, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.60 (p 0.0086, n 18) vs -0.04 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SOAT1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SOAT1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.45 p 0.110 (needs p < 3.8e-4)
Receipts
loading the receipts